论文部分内容阅读
强烈化疗治疗骨髓增生异常综合征(MDS)的预后因素尚不清楚。本文分析47例原发性MDS 患者在使用蒽环类抗生素-阿糖胞苷(Ara-C)联合化疗时,向急性髓性白血病(AML)发展前后的情况。
Prognostic factors for intensive chemotherapy in the treatment of myelodysplastic syndromes (MDS) are not yet known. This article analyzes the 47 patients with primary MDS in anthracycline-cytarabine (Ara-C) combined chemotherapy before and after the development of acute myelogenous leukemia (AML).